Antonia L. Moore
Research Subjects
Research Interests
Antonia L. Moore has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Andrew N. Phillips
2 shared publicationsMargaret A. Johnson
From the Department of Primary Care and Population Sciences and Centre for HIV Medicine, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, UK
2 shared publicationsAlessandro Cozzi-Lepri
From the Department of Primary Care and Population Sciences and Centre for HIV Medicine, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, UK
1 shared publicationCaroline A. Sabin
1 shared publicationClive Loveday
From the Department of Primary Care and Population Sciences and Centre for HIV Medicine, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, UK
1 shared publicationDarren Ransom
From the Department of Primary Care and Population Sciences and Centre for HIV Medicine, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, UK
1 shared publication
Latest Publications
- 1 March 2002
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (4) , 615-618
Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
Objective To assess the occurrence of viral load greater than 50 copies/ml in patients on highly active antiretroviral therapy (HAART) having achieved less than 50 copies/ml and the chance of whether a viral load greater than 50 copies/ml would lead to a sustained and increasing viral load. Design A cohort of 553 patients on HAART with viral loads of less than 50 copies/ml were followed. Results Over a median of 56 weeks 35% of patients experienced a transient increase and 8% virological failure (two consecutive viral loads of > 400 copies/ml). Transient increases and virological failure were more common in those with greater drug experience, and those with initial raised viral load values of more than 400 copies/ml were more likely to have a sustained increase and become virological failures. Conclusion Transient increases in viral load are common, mainly in the 50–400 copies/ml range, and the majority of subsequent viral load estimations show a return to less than 50 copies/ml. A single raised viral load should lead to adherence support and intensified monitoring. Subsequent treatment decisions can then be based on evidence of true virological rebound and failure.
- 1 March 2002
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (4) , 615-618
Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
Objective To assess the occurrence of viral load greater than 50 copies/ml in patients on highly active antiretroviral therapy (HAART) having achieved less than 50 copies/ml and the chance of whether a viral load greater than 50 copies/ml would lead to a sustained and increasing viral load. Design A cohort of 553 patients on HAART with viral loads of less than 50 copies/ml were followed. Results Over a median of 56 weeks 35% of patients experienced a transient increase and 8% virological failure (two consecutive viral loads of > 400 copies/ml). Transient increases and virological failure were more common in those with greater drug experience, and those with initial raised viral load values of more than 400 copies/ml were more likely to have a sustained increase and become virological failures. Conclusion Transient increases in viral load are common, mainly in the 50–400 copies/ml range, and the majority of subsequent viral load estimations show a return to less than 50 copies/ml. A single raised viral load should lead to adherence support and intensified monitoring. Subsequent treatment decisions can then be based on evidence of true virological rebound and failure.
- 1 February 2002
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 29 (2) , 197-202
Gender and Clinical Outcomes After Starting Highly Active Antiretroviral Treatment: A Cohort Study
Objective:To examine gender differences in clinical response to highly active antiretroviral treatment (HAART). Methods:A cohort of HIV-positive individuals was examined. Outcomes assessed were hospital admission and disease progression (either a new AIDS diagnosis or death) after starting HAART. Hazard ratios (HRs) derived using Cox regression methods compared female-to-male rates, adjusting for other factors independently associated with outcome. Results:Four hundred ninety-seven men and 146 women were followed up over a median of 13 months after starting HAART. Eighty-one percent of men were white, and 75% were homosexual. Fifty-eight percent of women were black African, and 86% were in the heterosexual risk category. The baseline CD4 count was higher in men than in women (191 vs. 145 × 10; p < .01), but viral loads were similar (5.2 vs. 5.1 log copies/ml, respectively; p = .13). Fifty-six percent of men and women were treatment naïve. Eighteen percent of men and women were admitted during follow-up, with 17% of male admissions and 12% of female admissions being the result of an AIDS-defining illness. The HR for admission was 0.76 (95% confidence interval [CI]: 0.46-1.27; p = .30) for women relative to men. Eleven percent of the men and 8% of the women experienced progression. Eighty-eight percent of progressions were the result of a new AIDS diagnosis (46 in men, 11 in women), and 8 men died. The HR for progression was 0.70 (CI: 0.36-1.33; p = .28). Conclusions:Our results suggest a possible benefit in women compared with men in the rate of outcomes after HAART. Further analysis with longer follow-up or greater numbers would enable a more powerful analysis to be performed. Address correspondence and reprint requests to Antonia L. Moore, Department of Primary Care and Population Sciences, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, U.K.; e-mail: [email protected] Manuscript received June 4, 2001; accepted October 12, 2001. © 2002 Lippincott Williams & Wilkins, Inc.
- 1 February 2002
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 29 (2) , 197-202
Gender and Clinical Outcomes After Starting Highly Active Antiretroviral Treatment: A Cohort Study
Objective:To examine gender differences in clinical response to highly active antiretroviral treatment (HAART). Methods:A cohort of HIV-positive individuals was examined. Outcomes assessed were hospital admission and disease progression (either a new AIDS diagnosis or death) after starting HAART. Hazard ratios (HRs) derived using Cox regression methods compared female-to-male rates, adjusting for other factors independently associated with outcome. Results:Four hundred ninety-seven men and 146 women were followed up over a median of 13 months after starting HAART. Eighty-one percent of men were white, and 75% were homosexual. Fifty-eight percent of women were black African, and 86% were in the heterosexual risk category. The baseline CD4 count was higher in men than in women (191 vs. 145 × 10; p < .01), but viral loads were similar (5.2 vs. 5.1 log copies/ml, respectively; p = .13). Fifty-six percent of men and women were treatment naïve. Eighteen percent of men and women were admitted during follow-up, with 17% of male admissions and 12% of female admissions being the result of an AIDS-defining illness. The HR for admission was 0.76 (95% confidence interval [CI]: 0.46-1.27; p = .30) for women relative to men. Eleven percent of the men and 8% of the women experienced progression. Eighty-eight percent of progressions were the result of a new AIDS diagnosis (46 in men, 11 in women), and 8 men died. The HR for progression was 0.70 (CI: 0.36-1.33; p = .28). Conclusions:Our results suggest a possible benefit in women compared with men in the rate of outcomes after HAART. Further analysis with longer follow-up or greater numbers would enable a more powerful analysis to be performed. Address correspondence and reprint requests to Antonia L. Moore, Department of Primary Care and Population Sciences, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, U.K.; e-mail: [email protected] Manuscript received June 4, 2001; accepted October 12, 2001. © 2002 Lippincott Williams & Wilkins, Inc.
- 1 January 2002
- Published by Wiley in The Obstetrician & Gynaecologist
- Vol. 4 (4) , 197-200
HIV and pregnancy
- 1 January 2002
- Published by Wiley in The Obstetrician & Gynaecologist
- Vol. 4 (4) , 197-200
HIV and pregnancy